FISEVIER

Contents lists available at ScienceDirect

Journal of the National Cancer Center





Full Length Article

Benefits and harms of screening for hepatocellular carcinoma in high-risk populations: systematic review and meta-analysis



Jichun Yang^{1,2}, Zhirong Yang^{3,4}, Xueyang Zeng², Shuqing Yu², Le Gao⁵, Yu Jiang¹, Feng Sun^{2,*}

¹ Department of Epidemiology and Biostatistics, School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

² Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China

³ Primary Care Unit, School of Clinical Medicine, University of Cambridge, Cambridgeshire, UK

⁴ Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China

⁵ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong,

China

ARTICLE INFO

Keywords: Hepatocellular carcinoma Screening Benefits Harms Meta-analysis

ABSTRACT

Objective: The incidence and mortality of hepatocellular carcinoma (HCC) have been increasing around the world. Current guidelines recommend HCC screening in high-risk population. However, the strength of evidence of benefits and harms of HCC screening to support the recommendation was unclear. The objective is to systematically synthesize current evidence on the benefits and harms of HCC screening.

Methods: We searched PubMed and nine other databases until August 20, 2021. We included cohort studies and RCTs that compared the benefits and harms of screening and non-screening in high-risk population of HCC. Case series studies that reported harms of HCC screening were also included. Pooled risk ratio (RR), according to HCC screening status, was calculated for each benefit outcome (e.g., HCC mortality, survival rate, proportion of early HCC), using head-to-head meta-analysis. The harmful outcomes (e.g., proportion of physiological harms provided by non-comparative studies were pooled by prevalence of meta-analysis. Analysis on publication bias and quality of life, subgroup analysis, and sensitivity analysis were also conducted.

Results: We included 70 studies, including four random clinical trials (RCTs), 63 cohort studies, three case series studies. The meta-analysis of RCTs showed HCC screening was significantly associated with reduced HCC mortality (RR [risk ratio], 0.73 [95% CI, 0.56–0.96]; $I^2 = 75.1\%$), prolonged overall survival rates (1-year, RR, 1.72 [95% CI, 1.13–2.61]; $I^2 = 72.5\%$; 3-year, RR, 2.86 [95% CI, 1.78–4.58]; $I^2 = 10.1\%$; and 5-year, RR, 2.76 [95% CI, 1.37–5.54]; $I^2 = 28.3\%$), increased proportion of early HCC detection (RR, 2.68 [95% CI, 1.77–4.06]; $I^2 = 50.4\%$). Similarly, meta-analysis of cohort studies indicated HCC screening was more effective than non-screening. However, pooled proportion of physiological harms was 16.30% (95% CI: 8.92%–23.67%) and most harms were of a mild to moderate severity.

Conclusion: The existing evidence suggests HCC screening is more effective than non-screening in high-risk population. However, harms of screening should not be ignored.

1. Introduction

Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death in the world, with an estimated global incidence of HCC per 100,000 person-years of 9.3 and a corresponding mortality of 8.5 in 2018.¹ The incidences of HCC in high-rate areas such as Asia and Africa remain high, while the incidences in low-rate areas such as Europe and the United States have been increasing.² China has the greatest number of cases (incidence of 17.5 per 100,000) and the world's largest population (1.4 billion).³ The total global disability adjusted life years (DALYs) of HCC increased from 13.31 million person-years in 1990 to 21.14 million person-years in 2016.⁴

The most common risk factors for HCC are infection with the Hepatitis B virus (HBV) or the Hepatitis C virus (HCV), excessive alcohol intake, obesity, type 2 diabetes, and aflatoxin.² Screening can help detect HCC at an early stage when it is amenable to curative therapy to reduce mortality.⁵ Most current guidelines^{6–8} recommend screening with ultrasound (US) with or without alpha-fetoprotein (AFP) every 6 months in high-risk population, i.e., those with HBV, HCV, and/or cirrhosis, as

E-mail address: sunfeng@bjmu.edu.cn (F. Sun).

https://doi.org/10.1016/j.jncc.2023.02.001

Received 25 October 2022; Received in revised form 30 December 2022; Accepted 3 February 2023

2667-0054/© 2023 Chinese National Cancer Center. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

^{*} Corresponding author.

well as other chronic liver diseases. However, current guidelines only cite the Zhang 2004 trial⁹ as the major source of evidence supporting the recommendations. The current guidelines do not rest on a systematic review of the current evidence or an evaluation of its strength.

The World Health Organization and American College of Physicians emphasize that "screening is not a single test but a comprehensive intervention with a cascade of subsequent events of either benefit or harm".^{10,11} Benefits are only found for truly positive patients who can be treated at the early stages of the disease. In other cases, screening can lead to harm to patients and a waste of resources. To determine whether a screening program is worth implementing, it is necessary to identify the benefits of screening against their harms and costs. The prognosis of HCC depends on the tumor stage. Patients detected in early stages can have higher survival rates resulting from transplantation or resection. Regorafenib and trans-arterial radioembolization represent valuable and relatively safe therapeutic options in intermediate/advanced HCC, whereas more advanced cases have a median survival of less than 1 year and a 3-year survival rate of only 27%.^{12,13} US and AFP are the most common screening modalities for HCC, and these have no direct physiological harm to patients and are of a relatively low cost.^{6,8} It is suggested that screening for HCC may be beneficial, but the harms of HCC screening (e.g., unnecessary biopsies, radiation exposure, and physiological anxiety) should not be ignored.^{5,10}

The U.S. Preventive Services Task Force (USPSTF) evaluated the benefits and harms of more than 10 kinds of evidence-based cancer screening by performing systematic reviews, such as lung, colorectal, and breast cancer screening,^{14–16} but they did not examine HCC screening. On the other hand, there only have been three qualitative reviews and two meta-analyses of the benefits of HCC screening.^{17–21} Two qualitative reviews published in 2003 and 2012 only summarized the random clinical trials (RCTs) of AFP and/or US for HCC screening in patients with HBV.^{17,20} Another qualitative review published in 2014 only reviewed studies that evaluated the benefits of HCC screening in patients with chronic liver disease.¹⁸ Only two meta-analyses have evaluated the benefits of HCC surveillance in patients with cirrhosis.^{19,21} Therefore, we performed a systematic review and meta-analysis to comprehensively assess the benefits and harms of HCC screening in all high-risk populations.

2. Materials and methods

We conducted and report this systematic review following the recommendations of the PRISMA 2020 statement.

2.1. Protocol and registration

This review was prospectively registered on the PROSPERO website as No. CRD42020148258 (https://www.crd.york.ac.uk/prospero/).

2.2. Search strategy

PubMed, Embase, the Cochrane library, Clinicaltrials.gov, Web of Science, Google scholar, and Chinese databases (CNKI, WanFang, VIP, and SinoMed) were searched from their inception to October 31, 2019, and an updated search was conducted through August 20, 2021. We used the keywords "screening" and "hepatocellular carcinoma" to search for relevant studies. The details of the search strategy are shown in Supplementary Table 1. In addition, we manually searched the reference lists of relevant reviews.

2.3. Study selection

Two reviewers (JCY and SQY) independently screened the titles and abstracts of studies based on the predefined inclusion and exclusion criteria. The reviewers resolved any discrepancies through discussion or, if necessary, by seeking a decision from a third reviewer (FS or ZRY). Studies were included if they met all of the following criteria: (i) study population including high-risk population of HCC (e.g., those with HBV, HCV, cirrhosis, and/or another chronic liver disease); (ii) interventions including screening modalities (e.g., AFP, US, CT, and MRI); (iii) comparators: non-screening; (iv) outcomes: benefits and/or harm outcomes (the outcomes of interest are listed below in Section 2.4); and (v) a study design in which the benefit outcomes were included in comparative studies (RCTs and cohort studies), and the harm outcomes were included in the comparative and non-comparative studies.

We excluded duplicate studies and studies in which outcome data were lacked or unavailable. Studies that compared different screening intervals or modalities were also excluded. If the same study was reported in more than one publication, we only included the most informative article or the longest follow-up study to avoid duplication of information.

2.4. Definition of outcomes

2.4.1. Outcomes of benefits

HCC mortality: This was the main benefit outcome, given that the goal of cancer screening is to reduce mortality. This is measured by the total number of deaths from HCC over a defined time interval (e.g., 1 year), divided by the number of people at risk for HCC in the population (screening population) during the same interval.²²

Survival rate: the number of people diagnosed with HCC who are still alive, for example, 1, 3, and 5 years after diagnosis, divided by the total number of HCC at those time points.²²

Proportion of early HCC: the total number of early HCC divided by the total number of HCC; this was the intermediate benefit outcome.

2.4.2. Outcomes of harms

Proportion of physiological harm: the number of people who suffer physiological harm from screening divided by the total screening population. Physiological harm is defined as any harm requiring subsequent follow-up testing related to false-positive or indeterminate screening results, which can be classified as mild (one diagnostic CT or MRI), moderate (multiple CT and/or MRI exams), or severe (any invasive evaluation, such as a biopsy or angiogram).²³

Proportion of psychological harm: the number of people who suffer psychological harm divided by the total screening population. Psychological harm includes any psychological problems (e.g., anxiety, psychological distress, and psychological anxiety) developed in response to positive screening results.¹⁶

2.5. Data extraction

The following information was extracted from each eligible study: basic information (first author, year of publication), population characteristics, screening modalities, screening intervals, benefits outcomes, harms outcomes, and study design. Two groups of reviewers (JCY with SQY and XYZ with LG) independently extracted data from the selected studies. The reviewers resolved any discrepancy through discussion or, if necessary, by seeking a decision from a third reviewer (FS or ZRY).

2.6. Assessment of risk of bias

Cochrane's tool for assessing risk of bias in randomized trials (CROB) was used to assess the risk of bias of RCTs based on seven domains.²⁴ If studies were rated as low risk of bias in at least four domains, it would be of moderate to high quality. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of cohort studies.²⁵ Each study was assigned from 0 to 9 stars across three domains: selection (0–4), comparability (0–2), and outcome (0–3). Studies with at least 6 stars were considered to be of moderate to high quality. We assessed case series studies with the National Institute for Clinical Excellence criteria (NICE).²⁶ Each item was assigned a score of 1 (yes) or 0 (no), and the scores were summed

across items to generate an overall study quality score. Studies with a quality score of at least 4 points were considered moderate to high quality. The reviewers resolved any discrepancy through discussion or, if necessary, by seeking a decision from a third reviewer (FS or ZRY).

2.7. Data synthesis and statistical analysis

2.7.1. Data synthesis

STATA software version 15.0 (StataCorp LP, College Station, TX) was used for all statistical analyses and to generate forest plots. We pooled results separately for RCTs and observational studies, as those studies are designed differently. Pooled risk ratios (RRs) according to HCC screening status were calculated for each benefit outcome (e.g., HCC mortality, survival rate, proportion of early HCC), using a random effects model of head-to-head meta-analysis. Harms outcomes (e.g., proportions of physiological and psychological harm) were provided by non-comparative studies and were pooled by prevalence of meta-analysis. The threshold for statistical significance was defined as P < 0.05. Heterogeneity was assessed with the chi-square test using Cochrane's Q statistic and was quantified using I^2 values.

2.7.2. Assessment of publication bias

For the symmetry of funnel plots, Egger's test was used to evaluate the presence of publication bias when 10 or more studies were available, and P < 0.05 was considered indicative of statistically significant publication bias.

2.7.3. Subgroup analyses

We performed pre-planned subgroup analyses according to screening modalities, screening population, screening intervals, whether the included studies adjusted lead-time bias, location of study, study period, proportion of Child Pugh C, and mean age of population to explore potential sources of heterogeneity.²⁷

2.7.4. Sensitivity analysis

We performed a sensitivity analysis by excluding studies with high risk of bias.

2.8. Rating the quality of evidence

Two reviewers (JCY and SQY) independently rated the quality of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. The reviewers resolved any discrepancies through discussion, if necessary, or by seeking a decision from a third reviewer (FS or ZRY). Based on the GRADE guideline, we downgraded the quality of evidence based on five dimensions (limitation, inconsistency, indirections, imprecision, and reporting bias) for RCTs and observational studies, and we only upgraded the quality of evidence on three dimensions (large effect, plausible confounding, and dose response) for observational studies.²⁸

3. Results

3.1. Literature search

The inclusion process is presented in the PRISMA diagram shown in Fig. 1. The database and manual searches yielded 7846 potentially relevant records. After abstracts and full texts were screened, 70 studies^{9,23,29-96} were ultimately included in the meta-analysis.

3.2. Characteristics of included studies

The characteristics of the included studies are summarized in Supplementary Table 2. All of the studies were published between 1990 and 2021. Four RCTs compared benefits outcomes in the HCC screening and non-screening groups. In all, 63 cohort studies compared benefits outcomes in the HCC screening and non-screening group; however, only 5 cohort studies^{34,68,83,91,96} provided the size of the screening population. Therefore, the total size of the screening population of cohort studies could not be obtained. In addition, three case series studies and one cohort study reported harms outcomes of HCC screening.

In addition, all RCTs had high risk of bias. However, only 11 cohort studies had high risk of bias. The three case series studies had low risk of bias. Details of the risk of bias assessment are presented in Supplementary Table 3–5.

3.3. Benefits of HCC screening

3.3.1. HCC mortality

As shown in Fig. 2, three RCTs^{9,35,88} and three cohort studies^{34,68,91} compared HCC mortality with and without screening. The meta-analysis of these RCTs (with 31,051 members of the screened population vs. 61,856 members of the population that were not screened) indicated that HCC mortality was significantly lower in the screened group (RR, 0.73 [95% CI, 0.56–0.96]; $I^2 = 75.1\%$). For the cohort studies (with 16,723 screened vs. 5365 not screened), metaanalysis of these cohort studies showed HCC mortality was significantly lower in the screened group (RR, 0.53 [95% CI, 0.36–0.78]; $I^2 = 8.1\%$). Because only three RCTs and cohort studies reported HCC mortality, subgroup, sensitivity, publication bias analyses were not conducted.

3.3.2. Survival rates

As shown in Supplementary Table 2, four RCTs and 47 cohort studies were included to assess overall survival in patients with screen-detected HCC versus those with HCC presenting symptomatically or who were diagnosed incidentally instead of being detected through screening. Most included studies have reported 1-, 3-, and 5-year survival rates, so these survival rates were used for the analysis.

As shown in Fig. 3, head-to-head meta-analyses of three RCTs (451 vs. 228 HCC patients) and 22 cohort studies (2714 vs. 3753 HCC patients) provided pooled 1-year survival rates in screen-detected HCC that were higher than those in the non-screening group, with the pooled RR being 1.72 (95% CI, 1.13–2.61; $I^2 = 72.5\%$) and 1.47 (95% CI, 1.35–1.59; $I^2 = 58.9\%$), respectively. In addition, subgroup analysis showed that the pooled 1-year survival rates differed according to screening intervals, adjusted for lead-time bias and study period. No significant differences were observed in the other subgroups, and the details are shown in Supplementary Table 6.

As shown in Fig. 4, head-to-head meta-analyses of three RCTs (435 vs. 218 HCC patients) and 26 cohort studies (5499 vs. 6064 HCC patients) suggested that the pooled 3-year survival rates for screen-detected HCC were higher than those in the non-screening group, with the pooled RR being 2.86 (95% CI, 1.78–4.58; $I^2 = 10.1\%$) and 1.58 (95% CI, 1.42–1.76; $I^2 = 68.9\%$), respectively. In addition, subgroup analysis showed that pooled 3-year survival rates differed after adjusting for lead-time bias and mean age No significant differences were observed in the other subgroups, and the details are shown in Supplementary Table 7.

As shown in Fig. 5, head-to-head meta-analyses of three RCTs (435 vs. 218 HCC patients) and 12 cohort studies (2886 vs. 3050 HCC patients) suggested that the pooled 5-year survival rates for screen-detected HCC were higher than those in the non-screening group, with the pooled RR being 2.76 (95% CI, 1.37–5.54; $I^2 = 28.3\%$) and 1.62 (95% CI, 1.47–1.79; $I^2 = 14.0\%$), respectively. No significant differences were observed in the subgroups, and the details are shown in Supplementary Table 8.





Study ID	RR (95% CI)	Screen events	Non-screen events	Weight (%)
Cohort Study				
Chen <i>et a</i> l.2002.7y	0.55 (0.30, 0.98)	68/4385	13/458	38.97
Yeh <i>et al.</i> 2014.2y	0.18 (0.04, 0.80)	3/8962	4/2152	6.59
Bui <i>et al.</i> 2019.5y	0.59 (0.36, 0.95)	28/3376	39/2755	54.44
Overall (I-squared = 8.1%, p = 0.337)	0.53 (0.36, 0.78)	99/16723	56/5365	100.00
RCT				
Chen <i>et al.</i> 2003.5y	0.80 (0.64, 0.99)	198/3712	125/1869	35.89
Zhang <i>et al.</i> 2004.5y	0.60 (0.52, 0.68)	322/9373	544/9443	41.92
Ji <i>et al.</i> 2018.4y	0.95 (0.63, 1.43)	30/17966	89/50544	22.19
Overall (I-squared = 75.1%, p = 0.018)	0.73 (0.56, 0.96)	550/31051	758/61856	100.00
NOTE: Weights are from random effects analysis				
0403	1	24.8		

Fig. 2. Comparison of hepatocellular carcinoma mortality between the screening group and the non-screening. CI, confidence interval; RCT, random clinical trail; RR, risk ratio; Y, years.

Study ID		RR (95% CI)	Screen	No screen	Weight (%
Cohort study					
Davila et al.2007.5y	· · · · · · · · · · · · · · · · · · ·	1.59 (1.04, 2.41)	21/44	34/113	2.75
Demma et al.2016.3y.A	· · · · · · · · · · · · · · · · · · ·	2.06 (1.39, 3.05)	55/108	24/97	3.00
El-Serag et al.2011.5y		1.58 (1.32, 1.88)	292/580	106/332	6.85
Gaba et al.2013.4y	•	1.29 (0.93, 1.81)	52/97	29/70	3.72
Gellert et al.2007.10y	· · · · · · · · · · · · · · · · · · ·	2.35 (1.39, 3.97)	13/27	25/122	1.93
Kemp et al.2005.12y		1.61 (1.23, 2.10)	36/41	30/55	4.84
Noda et al.2010.6y		1.44 (1.04, 2.01)	92/124	19/37	3.78
Poh et al.2015.2y		1.47 (0.93, 2.33)	13/24	32/87	2.38
Taura et al.2005.1y		2.25 (1.48, 3.41)	86/178	20/93	2.76
Thein et al.2015.10y		1.21 (1.08, 1.35)	199/302	295/540	8.51
Tong et al.2017.6y		1.35 (1.17, 1.56)	142/175	95/158	7.65
Tong et al.2010.6y	•	1.20 (1.00, 1.44)	24/26	40/52	6.63
Trevisani et al.2007.6y		1.33 (1.13, 1.56)	142/252	151/356	7.21
Van Meer et al.2015.5y		1.23 (1.12, 1.37)	200/295	428/779	8.77
Van et al.2005.1y		2.19 (1.42, 3.39)	27/47	22/84	2.59
Wong et al.2008.2y		1.87 (1.52, 2.31)	52/79	138/393	6.08
Wong et al.2000.5y		1.45 (0.81, 2.59)	11/16	9/19	1.65
Youk et al.2003.6y		1.27 (1.10, 1.46)	55/64	124/183	7.77
Chen et al.2017.8y		1.59 (1.25, 2.01)	144/186	40/82	5.48
Dixon et al.2018.3y		1.67 (1.14, 2.44)	17/25	31/76	3.13
Chinnaratha et al.2019.3y		1.44 (0.93, 2.24)	18/24	13/25	2.53
Overall (I-squared = 58.9%, <i>p</i> <0.001)	\diamond	1.47 (1.35, 1.59)	1691/2714	1705/3753	100.00
RCT	_				
Chen <i>et al.</i> 2003.5y	· · · · · · · · · · · · · · · · · · ·	2.52 (1.38, 4.62)	61/257	11/117	20.28
Zhang et al.2004.5y	· · · · · · · · · · · · · · · · · · ·	2.11 (1.44, 3.11)	57/86	21/67	27.06
Lu et al.2001.5y		1.65 (1.05, 2.60)	58/92	13/34	24.81
Singal et al.2021.2y		1.09 (0.76, 1.57)	14/16	8/10	27.84
Overall (I-squared = 72.5%, p = 0.012)		1.72 (1.13, 2.61)	190/451	53/228	100.00
NOTE: Weights are from random effects analysis					

Fig. 3. Comparison of 1-year survival rates between the screening group and the non-screening. CI, confidence interval; RCT, random clinical trail; RR, risk ratio; Y, years.

Cohort study 184 (134, 200) 243/392 69/182 6.11 Ando et al2005 Sy 177 (139, 216) 243/392 69/182 6.11 Costentin et al 2015 Ay 177 (139, 216) 272/877 82/488 5.88 Dawlie et al 2007 Sy 1156 (0.88, 275) 14/44 53/113 4.98 El Seage et al 2011 Sy 1156 (0.88, 275) 14/44 53/113 4.98 Leskue et al 2005 T2y 106/108 1097 57/00 0.92 Keing et al 2001 Sy 1097 57/00 0.92 216 (100, 4.23) 16/41 10055 1.84 Leskue et al 2005 C12y 100 (117, 767) 61/6 77/66 1.09 1.09 1.03 3.22 Starkat et al 2005 C12y 1000 (117, 767) 61/6 77/66 1.09 1.03 3.22 Starkat et al 2005 Ay 200 (113, 3.28) 91/124 1.037 3.22 Starkat et al 2005 Ay 1.84 (134, 2.00) 1.94 (14, 97, 71 1.68 Thein et al 2001 Sy 1.017 5.84 1.037 3.22 Starkat et al 2005 Ay 1.016 (114, 2.26) 5.84 1.017 <th>Study ID</th> <th>RR (95%</th> <th>SCI) Sc</th> <th>vents, E creen N</th> <th>Events, No screen</th> <th>Weight (</th>	Study ID	RR (95%	SCI) Sc	vents, E creen N	Events, No screen	Weight (
Andow <i>et al</i> 2006 Sy 1.64 (1.34, 2.00) 2.43/392 6.9/182 6.11 Consent <i>et al</i> 2016 4y A 1.15 (0.86, 1.54) 40/74 5.9/113 4.96 Davia <i>et al</i> 2007 Sy 1.56 (0.86, 2.54) 40/74 5.9/113 2.49 El-Sarag <i>et al</i> 2011.5y 1.56 (0.86, 2.54) 40/74 5.9/113 2.48 Gaba <i>et al</i> 2013.4y 1.56 (0.86, 2.54) 1.44 (0.52, 4.64) 10/97 57/05 1.64 Leykum <i>et al</i> 2007 Sy 1.44 (0.52, 4.64) 10/97 57/05 1.64 1.66 7.76 1.09 Leykum <i>et al</i> 2007 Sy 1.44 (0.52, 4.64) 10/97 57/05 1.64 1.97/76 0.92 Leykum <i>et al</i> 2007 Sy 1.66 7.76 1.09 1.66 7.76 1.09 Silveira <i>et al</i> 2007 Sy 2.09 (1.33, 3.28) 91/124 1.33/7 3.22 Satrar <i>et al</i> 2008 Sy 1.38 (1.41, 1.68) 1.44 (0.52, 4.50) 1.46 (0.52, 4.50) 1.46 (0.52, 4.50) 1.46 (0.52, 4.50) 1.56 (0.56, 1.56) 1.34 (5.57) 1.56 (0.56, 1.56) 1.34 (5.57) 1.34 (5.57) 1.56 (0.56, 2.56) 1.32 (5.54) 1.34 (5.57) 1.56 (0.56, 2.56) 1.56 (0.56, 2.56) </td <td>Cohort study</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Cohort study					
Chen et al 2002. Y Costemic et al 2005. Y Costemic et al 2007. Sy El-Serag et al 2017. Sy El-Serag et	Ando et al.2006.5y	1.64 (1.34,	2.00) 243	3/392 6	9/182	6.11
Costentin et al 2016 4y A Devia et al 2007 5y Elserage et al 2011 5y Gaste at al 2013 4y Hemp et al 2005 12y Kemp et al 2005 12y Kemp et al 2007 6y Starkar et al 2010 3y Starkar et al 2010 3y Starkar et al 2010 4y Elserage et al 2010 5y Elserage et al 2011 5y Costention 1 and	Chen et al.2002.7y	1.73 (1.39,	2.16) 272	2/877 8	2/458	5.86
Davide af 2007.5y 1444 23/113 2.40 Ex-Brage af 2011.5y 1.44 (0.52, 4.04) 1097 57/00 0.82 Kemp et al 2007.5y 2.15 (1.09, 4.23) 164 (1.07, 1.93) 12.248800 51/132 4.68 Kemp et al 2007.5y 2.15 (1.09, 4.23) 164/1 10/97 57/0 0.82 Kemp et al 2007.6y 2.15 (1.09, 4.23) 164/1 10/97 57/0 0.82 Sarkar et al 2012.1y 3.00 (1.17, 7.67) 67.6 7.76 1.93 7.23 Sarkar et al 2005.7y 2.03 (1.33, 2.28) 91/124 1.33/7 1.32 Sarkar et al 2006.1y 2.36 (1.44, 4.68) 87/4 93/7 1.65 Strakt et al 2008.8y 1.38 (0.82, 4.31) 10/17 57/6 1.34 Strakt et al 2006.1y 2.36 (1.44, 4.68) 87/4 93/7 1.65 Transk et al 2007.6y 2.06 (1.03, 3.22) 91/124 1.30/7 3.22 Transk et al 2007.6y 1.36 (1.41, 1.66) 124/4022 161/164 6.30 Toog et al 2007.6y 1.89 (1.63, 2.18) 55/6/1080 160/059 1.68 4.32 <	Costentin et al.2016.4y.A	1.15 (0.86,	1.54) 40/	74 5	3/113	4.96
El-Serag et al 2011 5y Gaba et al 2013 4y Kem et al 2005.12y Kuo et al 2005 5,12y Kuo et al 2010 3y Start et al 2007 6y Noda et al 2010 4y Start et al 2007 6y Start et al 2010 5y Start et a	Davila et al.2007.5y	1.56 (0.89,	2.75) 14/	44 2	3/113	2.40
Gaba <i>et al</i> 2013. 4y 1.44 (0.52, 4.04) 1097 570 0.52 Kemp <i>et al</i> 2005. 12y 2.15 (10.9, 4.23) 164/1 1055 1.84 Leykum <i>et al</i> 2007. 6y 3.00 (1.17, 767) 6/16 7/56 1.09 Noda <i>et al</i> 2010. 6y 3.00 (1.17, 767) 6/16 7/56 1.09 Starka <i>et al</i> 2012. 11y 2.05 (1.33, 3.28) 9/11/21 20/31/22 20/07 3.35 Starka <i>et al</i> 2016. 10y 2.35 (1.14, 4.86) 8/14 9/37 1.65 Starka <i>et al</i> 2016. 10y 2.15 (1.99, 3.32) 9/11/22 20/107 3.55 Tong <i>et al</i> 2015. 10y 1.33 (1.14, 1.66) 12/2/182 20/302 6.54 Tong <i>et al</i> 2016. 5y 1.06/26 19/52 30/7 1.68 4.79 Yang <i>De et al</i> 2007. 5y 1.68 (1.63, 2.18) 53/4/1060 16/26 19/52 30/7 Toryoda <i>et al</i> 2006. 5y 1.189 (1.63, 2.18) 53/4/1060 16/26 19/52 30/7 Yang <i>De et al</i> 2007. 5y 1.68 (1.63, 2.18) 53/4/1060 16/26 19/52 30/7 Yang <i>De et al</i> 2006. 5y 1.19 (0.08, 1/7.51)	El-Serag et al.2011.5y	1.44 (1.07,	1.93) 128	8/580 5	1/332	4.86
Kemp et J2005.12y 215 (10, 4, 23) 16/41 10/055 1.84 Leykum et J2007.6y 300 (11, 17, 767) 67/16 7.66 1.09 Noda et J2010.6y 300 (11, 17, 767) 67/16 7.66 1.09 Stark et at J2017.1y 235 (11, 4, 486) 81/4 9/37 1.85 Silveira et J2008.7y 2.15 (13, 3, 32.9) 91/124 13/37 3.22 Silveira et J2008.7y 2.15 (13, 3, 32.6) 91/124 13/37 3.25 Silveira et J2008.7y 2.15 (13, 3, 32.6) 91/124 13/37 3.26 Tennie ret J2005.12y 1.38 (14, 2, 166) 12/162 10/3/202 6.54 Them et J2005.12y 1.33 (11, 1.56) 12/21/82 10/3/202 6.54 Torg et J2010.6y 1.38 (14, 1.66) 12/3/20 16.54 195/2 307 Torg et J2010.6y 1.08 (140, 2.69) 16/26 19/52 307 Torg et J2010.6y 1.38 (14, 1.68) 16/26 19/52 307 Torg et J2010.5y 1.09 (0.86, 1.75) 11/16 11/19 0.15 Yang De et J2005.5y 1.35 1.36 (14, 2.69)	Gaba et al.2013.4y	1.44 (0.52,	4.04) 10/	/97 5	/70	0.92
Kuo et al 2010 3y 1.40 (12.91, 15.3) 222/218 581/1118 7.46 Leykum et al 2007.6y 300 (1.17, 767) 6/16 7/56 1.08 Sarkar et al 2010.6y 2.09 (1.33, 2.38) 91/124 133/7 3.22 Strakit et al 2008.7y 1.88 (0.82, 4.31) 10/17 5/16 1.34 Strakit et al 2006.8y 1.38 (0.82, 4.31) 10/17 5/16 1.34 Tanaka et al 2005.1y 1.38 (0.82, 4.31) 10/17 5/16 1.34 Tong et al 2015.10y 1.38 (1.14, 1.66) 124/302 16/16/40 6.30 Tong et al 2010.6y 1.68 (1.05, 2.69) 16/26 19/52 3.07 Tong et al 2005.5y 1.68 (1.05, 2.69) 16/26 19/52 3.07 Toyoda et al 2007.6y 1.68 (1.05, 2.18) 536/1050 160/991 6.84 Van Meer et al 2005.5y 1.68 (1.63, 2.18) 536/1050 160/991 6.84 Van J Det al 2000.5y 1.91 (0.08, 1.76) 1/16 1/19 0.18 Van J Det al 2001.3y 1.91 (0.08, 1.76) 1/16 1/19 0.18 Van Meer et al 2003.5y 1.92 (0.08, 5.62) <td>Kemp et al.2005.12y</td> <td>2.15 (1.09,</td> <td>4.23) 16/</td> <td>/41 1</td> <td>0/55</td> <td>1.84</td>	Kemp et al.2005.12y	2.15 (1.09,	4.23) 16/	/41 1	0/55	1.84
Laykum et al 2007. 6y Noda et al 2010. 6y Sakar et al 2012. 11y Silveria et al 2008. 7y Silveria et al 2006. 12y Tanak et al 2006. 12y Tanak et al 2006. 12y Tanak et al 2006. 12y Silveria et al 2007. 5y Silveria et al 2005. 5y Silveria et al 2005	Kuo et al.2010.3y	1.40 (1.29,	1.53) 232	2/318 5	81/1118	7.46
Noda et al 2010 6y 209 (133, 328) 91/124 1337 3.28 Sarkar et al 2012.11y 2.35 (1.14, 4.86) 01/4 9/37 1.65 Stravit et al 2008.7y 2.35 (1.14, 4.86) 01/17 5/16 1.34 Stravit et al 2008.12y 1.38 (1.14, 1.66) 122/182 103/202 6.54 Them et al 2015.10y 1.38 (1.14, 1.66) 124/302 161/540 6.30 Tong et al 2017.5y 1.06/26 19/92 3.07 3.05 Tong et al 2016.6y 1.88 (1.68, 2.18) 536/1050 160/591 6.84 Trevisani et al 2005.5y 1.58 (1.42, 1.86) 131/225 228/779 6.55 Wong L et al 2005.5y 1.19 (0.08, 17.51) 1/16 1/19 0.15 Yang JD et al 2011.3y Youk et al 2005.5y 1.19 (0.08, 17.51) 1/16 1/19 0.15 Yang JD et al 2011.3y Youk et al 2005.5y 1.19 (0.08, 17.51) 1/16 1/19 0.15 Yang JD et al 2011.3y Youk et al 2003.6y 1.99 (0.37, 51) 1/16 1/19 0.15 Chen et al 2015.3y 2.05 (1.07, 3.92) 45/25 1.17 0.77	Leykum et al.2007.6y	3.00 (1.17,	7.67) 6/1	6 7	/56	1.09
Sarkar et al. 2012; 1 y 2.35 (1.14, 4.66) 8/14 9/37 1.65 Silveira et al. 2008; y 1.88 (0.82, 4.31) 10/17 5/16 1.34 Silveira et al. 2008; y 1.38 (0.82, 4.31) 10/17 5/16 1.34 Sinveira et al. 2008; y 1.33 (1.11, 1.156) 122/182 103/202 6.54 Thenis et al. 2015; 10y 1.38 (1.14, 1.66) 124/302 161/54.0 6.30 Tong et al. 2015; 10y 1.38 (1.14, 1.66) 124/302 161/54.0 6.30 Tong et al. 2005; y 1.66 (1.05, 2.69) 160/56 160/51 6.84 Trevisani et al. 2007; 6y 1.89 (1.63, 2.18) 536/1050 160/51 6.84 Van Meer et al. 2015; 5y 1.53 (1.28, 1.61) 11/16 11/19 0.15 Yan Ger et al. 2015; 5y 1.53 (1.28, 1.61) 131/125 228/77 6.55 Wong L et al. 2000; 5y 1.53 (1.28, 1.61) 131/18 1/19 0.15 Yan et et al. 2017; 3y 2.49 (1.59, 3.89) 96/186 17/82 3.27 Dixon et al. 2018; 3y 1.16 (1.14, 2.26) 5/25 6/76 0.91 Chinnarathe et	Noda et al.2010.6y	2.09 (1.33,	3.28) 91/	/124 1	3/37	3.22
Silveira et al.2008.7y Stravite et al.2008.8y Tanaka et al.2006.12y Thein et al.2005.12y Tong et al.2005.12y Tong et al.2007.6y Tong et al.2007.6y Tory dat al.2007.6y Trevisani et al.2007.6y Thein et al.2015.5y Wong Let al.2007.6y Tory dat al.2008.5y Tory dat al.2009.6y Tory dat al.2009.7y Tory data al.2009.7y Tory	Sarkar et al.2012.11y	2.35 (1.14,	4.86) 8/1	4 9	/37	1.65
Stravitz et al 2008. 8y 2.15 (1.33, 3.2) 69/172 20/107 3.35 Tanaka et al 2006. 12y 1.31 (1.11, 1.56) 122/182 103/202 6.54 Thein et al 2015. 10y 1.38 (1.14, 1.66) 122/182 103/202 6.54 Tong et al 2010. 6y 1.38 (1.14, 1.66) 122/182 103/202 6.54 Tong et al 2010. 6y 1.38 (1.14, 1.66) 122/182 103/202 8.57 Tong et al 2010. 6y 1.38 (1.14, 1.66) 122/182 103/202 8.57 Tong et al 2010. 6y 1.98 (1.62, 2.18) 536/1050 160/591 6.84 Trevisani et al 2007. 6y 1.89 (1.63, 2.18) 536/1050 160/591 6.84 Van Meer et al 2011. 3y 1.19 (0.08, 17.51) 11/16 11/19 0.15 Yang JD et al 2013. 3y 1.09 (0.86, 1.16) 88/136 19/307 6.79 Youk et al 2003. 8y 1.05 (0.74, 1.44) 26/64 71/183 4.32 Chen et al 2017. 8y 1.00 (0.86, 1.16) 88/136 19/307 6.79 Dixon et al 2018. 3y 60/16 17/182 3.27 Dixon et al 2018. 3y 60/16	Silveira et al.2008.7y	1.88 (0.82,	4.31) 10/	/17 5	/16	1.34
Tanaka et al.2006.12y 1.31 (1.11, 1.56) 122/182 103/202 6.54 Thein et al.2015.10y 1.38 (1.14, 1.66) 124/302 101/540 6.30 Tong et al.2017.5y 2.12 (1.57, 2.87) 94/175 40/158 4.79 Tong et al.2016.5y 1.88 (1.05, 2.69) 160/26 19/52 3.07 Toryoda et al.2006.5y 1.89 (1.63, 2.18) 536/1050 160/591 6.84 Yan Meer et al.2015.5y 1.51 (1.14, 2.26) 58/252 51/356 4.32 Van Meer et al.2015.5y 1.53 (1.29, 1.81) 131/295 226/779 6.55 Wong L et al.2003.5y 1.16 (1.14, 2.26) 80/252 51/356 4.32 Yan JD et al.2017.8y 1.00 (0.86, 17.16) 88/136 199/307 6.76 Youk et al.2003.5y 1.19 (0.08, 17.51) 11/16 11/9 0.15 Yan JD et al.2017.8y 1.05 (0.74, 1.48) 28/64 71/183 4.23 Dixon et al.2018.9y 2.04 (1.59, 3.89) 96/186 17/82 3.27 Chen et al.2001.5y, RCT 2.99 (0.33, 5.62) 11/24 5/25 1.17 Overall (I-squared = 10.1%, p = 0.	Stravitz et al.2008.8y	2.15 (1.39,	3.32) 69/	/172 2	0/107	3.35
Their al 2015.10y 1.38 (1.14, 1.66) 124/002 161/540 6.30 Tong et al 2017.5y 2.12 (1.57, 2.87) 94/175 40/158 4.79 Tong et al 2010.6y 1.68 (1.05, 2.69) 16/26 19/52 3.07 Trevisani et al 2017.6y 1.68 (1.05, 2.69) 16/26 19/52 3.07 Trevisani et al 2017.6y 1.68 (1.05, 2.69) 16/26 19/52 3.07 Van Meer et al 2015.5y 1.61 (1.14, 2.26) 58/252 51/356 4.32 Van JD et al 2001.3y 1.99 (1.68, 2.18) 58/252 51/356 4.32 Van JD et al 2011.3y 1.99 (0.08, 1.75) 1.1/16 11/19 0.15 Yang JD et al 2003.6y 1.05 (0.74, 1.48) 26/64 71/183 4.23 Chen et al 2018.3y 2.49 (1.59, 3.89) 96/186 17/82 3.27 Dixon et al 2018.3y 2.49 (1.98, 3.89) 96/186 17/82 3.27 Chen et al 2001.3y 2.29 (0.33, 5.62) 11/24 5/25 1.17 Overall (1-squared = 6.9%, p < 0.001)	Tanaka et al.2006.12y	1.31 (1.11,	1.56) 122	2/182 1	03/202	6.54
Tong et al.2017. 5y 2.12 (157, 2.87) 94/175 40/158 4.79 Tong et al.2010. 6y 1.68 (1.05, 2.69) 16/26 19/52 3.07 Toryda et al.20205. 5y 1.89 (1.53, 2.19) 536/1050 160/591 6.84 Trevisani et al.2007. 6y 1.61 (1.14, 2.26) 58/252 51/356 4.32 Van Meer et al.2015. 5y 100 (0.86, 1.16) 88/136 199/307 6.79 Youk et al.2003. 6y 1.09 (0.86, 7.15) 11/16 1/19 0.15 Yan Meer et al.2015. 5y 100 (0.86, 1.16) 88/136 199/307 6.79 Youk et al.2003. 6y 1.09 (0.86, 7.15) 11/16 1/183 4.23 Chen et al.2017. 8y 2.49 (1.59, 3.89) 96/166 17/82 3.27 Dixon et al.2018. 3y Control et al.2019. 3y 2.29 (0.93, 5.62) 11/12 5/25 1.17 Overall (1-squared = 68.9%, p < 0.001)	Thein et al.2015.10y	1.38 (1.14,	1.66) 124	4/302 1	61/540	6.30
Tong et al 2010. 6y 1688 (1.05, 2.69) 16/26 19/52 3.07 Toyoda et al 2006. 5y 1.89 (1.63, 2.18) 536/1050 160/591 6.84 Trevisani et al 2007. 6y 1.61 (1.14, 2.26) 58/252 57/356 4.32 Van Meer et al 2015. 5y 1.53 (1.29, 1.81) 131/295 226/779 6.55 Wong L et al 2000. 5y 1.91 (0.08, 17.51) 11/16 11/9 0.15 Yang UD et al 2011. 3y 1.00 (0.86, 17.61) 88/136 199/307 6.79 Youk et al 2003. 6y 1.05 (0.74, 1.48) 26/64 71/183 4.23 Dixon et al 2018. 3y 2.49 (1.59, 3.89) 96/186 17/82 3.27 Chen et al 2013. 5y 3.04 (1.08, 8.56) 6/25 6/76 0.91 Chinnaratha et al 2018. 3y 3.04 (1.08, 8.56) 6/25 6/76 0.91 Chen et al 2003. 5y, RCT 2.99 (0.33, 5.62) 11/24 5/25 1.17 Overall (I-squared = 10.1%, p = 0.329) NOTE: Weights are from random effects analysis 3.010 (1.34, 7.19) 20/218 100.00	Tong et al.2017.5y	2.12 (1.57,	2.87) 94/	/175 4	0/158	4.79
Toyoda et al 2006 5y 189 (183, 218) 536/1050 160/591 6.84 Trevisani et al 2017.6y 1.51 (1.14, 226) 538/252 51/356 4.32 Van Meer et al 2015 5y 1.51 (1.29, 181) 131/295 226/779 6.55 Yang JD et al 2001.3y 1.91 (0.08, 17.51) 11/16 11/19 0.15 Yang JD et al 2011.3y 100 (0.86, 116) 881/385 199/307 6.79 Youk et al 2003.6y 1.05 (0.74, 1.48) 26/64 71/183 4.23 Other at al 2017.8y 1.05 (0.74, 1.48) 26/64 71/183 4.23 Dokon et al 2018.3y 2.49 (1.59, 3.89) 96/186 17/82 3.27 Dokon et al 2018.3y 2.29 (0.33, 5.62) 11/24 5/25 1.17 Overall (1-squared = 68,9%, p < 0.001)	Tong et al.2010.6y	• 1.68 (1.05,	2.69) 16/	/26 1	9/52	3.07
Trevisani et al 2007. 6y 1.61 (1.14, 2.26) 58/252 51/356 4.32 Van Meer et al 2015. 5y 1.53 (1.29, 1.81) 1.53 (1.29, 1.81) 1.53 (1.29, 1.81) 1.53 (1.29, 1.81) 1.51 (1.14, 2.26) 58/252 51/356 4.32 Van G L et al 2001. 5y 1.53 (1.29, 1.81) 1.51 (1.14, 2.26) 58/252 51/356 4.32 Yang L et al 2001. 5y 1.53 (1.29, 1.81) 1.51 (1.16, 2.26) 58/252 51/356 4.32 Yan Keer et al 2001. 5y 1.05 (0.74, 1.81) 28/136 199/307 6.79 Youk et al 2003. 6y 1.05 (0.74, 1.48) 26/64 71/183 4.23 Chen et al 2018.3y 0.61 (1.68, 8.58) 6/25 6/76 0.91 Chinnaratha et al 2019.3y 0.0verall (1.equared = 68.9%, p.<0.001)	Toyoda et al.2006.5y	1.89 (1.63,	2.18) 536	6/1050 1	60/591	6.84
Van Meer et al 2015. 5y 1.53 (1.29, 1.81) 131/295 226/779 6.55 Wong L et al 2000.5y 1.19 (0.08, 17.51) 11/6 11/9 0.15 Yang JD et al 2011.3y 1.00 (0.86, 17.51) 11/6 19/9307 6.79 Youk et al 2003.6y 1.05 (0.74, 1.48) 28/64 71/183 4.23 Chen et al 2017.8y 2.49 (1.59, 3.89) 96/186 17/82 3.27 Dixon et al 2019.3y 3.04 (1.08, 8.56) 6/25 6/76 0.91 Chen et al 2003.5y read 1.58 (1.42, 1.76) 248/6499 198/76064 100.00 RCT Chen et al 2003.5y RCT 2.05 (1.07, 3.92) 45/257 10/117 45.39 Chen et al 2001.5y, RCT 2.05 (1.07, 3.92) 45/257 10/117 45.39 Chen et al 2001.5y, RCT 2.05 (1.07, 3.92) 45/257 10/117 45.39 Cher et al 2001.5y, RCT 3.10 (1.34, 7.19) 2.192 5/34 2.87 Overall (I-squared = 10.1%, p = 0.329) NOTE: Weights are from random effects analysis 100.00 NOTE 11/1435 20/218 100.00	Trevisani et al.2007.6y	• 1.61 (1.14,	2.26) 58/	/252 5	1/356	4.32
Wong Let al 2000.5y 1.19 (0.08, 17.51) 1/16 1/19 0.15 Yang JD et al /2011.3y 1.00 (0.86, 1.16) 88/136 199/307 6.79 Youk et al /2013.8y 1.05 (0.74, 1.48) 26/64 71/183 4.23 Chen et al /2017.8y 2.49 (1.56, 3.89) 96/186 17/82 3.27 Dixon et al /2018.3y 2.49 (1.98, 3.89) 96/186 17/82 3.27 Okon et al /2018.3y 2.29 (0.33, 5.62) 11/24 5/25 1.17 Overall (I-squared = 68.9%, p < 0.001)	Van Meer et al.2015.5y	1.53 (1.29,	1.81) 131	1/295 2	26/779	6.55
Yang Det al.2011.3y 100 (0.86, 1.16) 88/136 199/307 6.79 Youk et al.2003.6y 1.05 (0.74, 1.48) 26/64 71/183 4.23 Chen et al.2017.8y 2.49 (1.59, 3.89) 96/166 17/82 3.27 Dixon et al.2018.3y 3.04 (1.08, 8.58) 6/25 6/76 0.91 Chinnaratha et al.2019.3y 0verall (1-squared = 68.9%, p < 0.001)	Wong L et al.2000.5y	1.19 (0.08,	17.51) 1/1	6 1	/19	0.15
Youk et al 2003.6y 105 (0.74, 1.48) 26/64 71/183 4.23 Chen et al 2017.8y 2.49 (1.59, 3.89) 96/186 17/82 3.27 Dixon et al 2018.3y 3.04 (1.08, 8.56) 6/25 6/76 0.91 Chinaratha et al 2019.3y 3.04 (1.08, 8.56) 6/25 6/76 0.91 Qverall (1-squared = 68.9%, p < 0.001)	Yang JD et al.2011.3y	1.00 (0.86,	1.16) 88/	/136 1	99/307	6.79
Chen et al.2017.8y 2.49 (1.59, 3.89) 96/186 17/62 3.27 Dixon et al.2018.3y 3.04 (1.08, 8.58) 6/25 6/76 0.91 Chinnaratha et al.2019.3y 3.04 (1.08, 8.58) 6/25 6.17 1.01 Overall (I-squared = 68.9%, p < 0.001)	Youk et al.2003.6y	1.05 (0.74,	1.48) 26/	/64 7	1/183	4.23
Dixon et al.2018.3y 3.04 (1.08, 8.58) 6/25 6/76 0.91 Chinaratha et al.2019.3y 2.29 (0.93, 562) 11/24 5/25 1.17 Overall (I-squared = 68.9%, p < 0.001)	Chen et al.2017.8y	2.49 (1.59,	3.89) 96/	/186 1	7/82	3.27
Chinaratha et al (2013 yr) 2 29 (0.33, 5 62) 11/24 5/25 1.17 Overall (I-squared = 68,9%, p < 0.001)	Dixon et al.2018.3y	3.04 (1.08,	8.58) 6/2	25 6	/76	0.91
Overall (I-squared = 68.9%, p < 0.001)	Chinnaratha et al.2019.3y	2.29 (0.93,	5.62) 11/	/24 5	/25	1.17
RCT 2.05 (1.07, 3.92) 45/257 10/117 45.39 Zhang <i>et al.</i> 2004.5y, RCT 4.67 (1.92, 11.40) 30/86 5/67 25.82 Lu <i>et al.</i> 2001.5y, RCT 3.10 (1.34, 7.19) 42/92 5/34 28.79 Vorrall (1-squared = 10.1%, <i>p</i> = 0.329) 8.66 (1.78, 4.58) 117/435 20/218 100.00	Overall (I-squared = 68.9%, p <0.001)	> 1.58 (1.42,	1.76) 244	48/5499 1	987/6064	100.00
Chen et al.2003.5y.RCT 2.05 (1.07, 3.92) 45/257 10/117 45.39 Zhang et al.2004.5y.RCT 4.67 (1.92, 11.40) 30/86 5/67 25.82 Lu et al.2001.5y.RCT 3.10 (1.34, 7.19) 42/92 5/34 28.79 Overall (+squared = 10.1%, p = 0.329) NOTE: Weights are from random effects analysis 117/435 20/218 100.00	RCT					
Zhang et al.2004.5y.RCT 4.67 (1.92, 11.40) 30/86 5/67 25.82 Lu et al.2001.5y.RCT 3.10 (1.34, 7.19) 42/92 5/34 28.79 Overall (I-squared = 10.1%, p = 0.329) 2.86 (1.78, 4.58) 117/435 20/218 100.00 NOTE: Weights are from random effects analysis 0.000 0.000 0.000 0.000	Chen et al.2003.5y.RCT	2.05 (1.07,	3.92) 45/	/257 1	0/117	45.39
Lu <i>et al.</i> 2001.5 <i>y</i> .RCT Overall (I-squared = 10.1%, <i>p</i> = 0.329) NOTE: Weights are from random effects analysis	Zhang et al.2004.5y.RCT	4.67 (1.92,	11.40) 30/	/86 5	/67	25.82
Overall (I-squared = 10.1%, p = 0.329) 2.86 (1.78, 4.58) 117/435 20/218 100.00 NOTE: Weights are from random effects analysis 100.00 100.00 100.00 100.00	Lu et al.2001.5y.RCT	3.10 (1.34,	7.19) 42/	/92 5	/34	28.79
NOTE: Weights are from random effects analysis	Overall (I-squared = 10.1%, p = 0.329)	2.86 (1.78,	4.58) 117	7/435 2	0/218	100.00
	NOTE: Weights are from random effects analysis					
		1				

Fig. 4. Comparison of 3-year survival rates between the screening group and the non-screening. CI, confidence interval; RCT, random clinical trail; RR, risk ratio; Y, years.

Study ID		RR (95% CI)	Events, Screen	Events, No screen	Weight (%)
Cohort study					
Ando <i>et al</i> .2006.5y		1.54 (1.14, 2.07)	139/392	42/182	9.47
El-Serag <i>et al</i> .2011.5y	•	1.21 (0.83, 1.75)	76/580	36/332	6.36
Gellert <i>et al</i> .2007.10y	*	2.71 (0.69, 10.66)	3/27	5/122	0.52
Noda <i>et al</i> .2010.6y		1.90 (0.99, 3.64)	51/124	8/37	2.26
Tanaka <i>et al</i> .2006.12y		1.43 (1.11, 1.85)	84/182	65/202	12.23
Thein <i>et al</i> .2015.10y		1.53 (1.21, 1.94)	96/302	112/540	14.00
Tong <i>et al.</i> 2017.5y	•	2.71 (1.76, 4.17)	66/175	22/158	4.87
Tong <i>et al.</i> 2010.6y	• • • • • • • • • • • • • • • • • • •	2.50 (1.12, 5.57)	10/26	8/52	1.50
Trevisani <i>et al</i> .2007.6y	•	2.21 (1.20, 4.05)	25/252	16/356	2.57
Van <i>et al.</i> 2015.5y		1.68 (1.38, 2.05)	109/295	171/779	17.71
Chen <i>et al.</i> 2017.8y	•	1.87 (1.18, 2.96)	72/186	17/82	4.33
Pinero et al.2019.5y		1.55 (1.32, 1.81)	252/345	98/208	24.19
Overall (I-squared = 14.0%, p = 0.308)	\diamond	1.62 (1.47, 1.79)	983/2886	600/3050	100.00
RCT					
Chen et al.2003.5y	•	1.37 (0.45, 4.15)	12/257	4/117	29.59
Zhang et al.2004.5y	•	4.87 (1.78, 13.32)	25/86	4/67	34.16
Lu <i>et al</i> .2001.5y	•	2.86 (1.09, 7.51)	31/92	4/34	36.25
Overall (I-squared = 28.3%, p = 0.248)		2.76 (1.37, 5.54)	68/435	12/218	100.00
NOTE: Weights are from random effects analysis					
		12.2			

Fig. 5. Comparison of 5-year survival rates between the screening group and the non-screening. CI, confidence interval; RCT, random clinical trail; RR, risk ratio; Y, years.

3.4. Benefits of HCC screening: proportion of early HCC

As presented in Fig. 6, four RCTs (492 vs. 322 HCC patients) and 50 cohort studies (9908 vs. 12,433 HCC patients) investigated the proportion of early HCC in the screening versus the no-screening group. A meta-analysis of the RCTs ((RR, 2.68 [95% CI, 1.77–4.06]; $I^2 = 50.4\%$) and cohort studies ((RR, 2.16 [95% CI, 2.00–2.34]; $I^2 = 81.9\%$) indicated that patients who underwent screening were significantly more likely to have their HCC found in an early stage. The results of subgroup analysis suggest that mean age of HCC may affect the association. No significant differences were observed in the other subgroups, and the details are shown in Supplementary Table 9.

3.5. Harms of HCC screening: proportion of physiological harm

No previous studies have reported or quantified the proportion of psychological harm caused by HCC screening. Three case series studies^{23,70,94} and one cohort study⁹⁶ reported the proportion of physiological harm. The cohort study compared the benefits outcomes of the screening versus the non-screening group and reported the proportion of physiological harm in the screening group. Therefore, four studies evaluated the physiological harm caused by HCC screening in 2578 cirrhosis studies where participants underwent at least one AFP or US screening. After 2 or 3 years of follow-up, the proportion of physiological harm in the screening population was calculated.

The results of meta-analysis are shown in Fig. 7. The pooled proportion of physiological harm was 16.30% (95% CI, 8.92%–23.67%). However, there was significant heterogeneity among the included studies ($I^2 = 95.7\%$, P < 0.01). Because only study location and years of follow-up differed among the included studies, we conducted subgroup analyses based on study location and years of follow-up as grouping fac-

tors. The heterogeneity was slightly reduced by the subgroup analysis using years of follow-up while using location of study did not change. This suggests that years of follow-up may influence the proportion of physiological harm.

In addition, three of four included studies classified the severity of physiological harm, so we also pooled the proportion of mild (10.88% [95% CI, 5.80%-15.95%]), moderate (6.32% [95% CI, 0.82%-11.83%]), and severe physiological harm (0.31% [95% CI, 0.08%-0.54%]) based on those three studies (Fig. 8).

3.6. Sensitivity analyses

As shown in Supplementary Table 10, no significant change was seen in the results before and after the exclusion of studies with high risk of bias.

3.7. Publication bias

As shown in Supplementary Fig. 1–4, the funnel plot analysis of publication bias suggests that there was potential publication bias in 1-year survival rates and proportion of early HCC. No significant publication bias was observed in 3- and 5-year survival rates.

3.8. Quality of evidence

As shown in Supplementary Table 11, the quality of evidence was very low for each benefit outcome according to GRADE guidelines. GRADE is only used to rate the quality of pooled evidence from comparative studies such as RCTs and cohort studies, while the proportion of physiological harm was provided by non-comparative studies. Therefore, the proportion was not evaluated using GRADE. However, there is

- .

			Events,	Events,	
Study ID		RR (95% CI)	Screen	No screen	Weight (%)
Study ID Cohort study Ando et al.2005. Sy Caures et al.2007. 3y Chalteerakij et al.2017. 1y Cheung et al.2006. Sy Chine et al.2016. 5y Cheung et al.2016. 5y Cheung et al.2016. 5y Garcia et al.2017. 10y Garcia et al.2017. 10y Garcia et al.2017. 10y Jou et al.2010. 11y Khalat et al.2016. 5y Khalat et al.2016. 5y Mittal et al.2016. 5y Nusbaum et al.2015. 2y Pascual et al.2016. 5y Nusbaum et al.2015. 2y Pascual et al.2017. 8y Stroffolini et al.2017. 11y Strata et al.2017. 12y Strata et al.2016. 12y Tanaka et al.2016. 12y Tanaka et al.2016. 12y Tanaka et al.2017. 5y Toydg et al.2011. 1y Strata et al.2017. 5y Toydg et al.2016. 1y Yang et al.2017. 5y Toydg et al.2016. 1y Yang et al.2016. 1y Tanaka et al.2017. 5y Toydg et al.2016. 1y Yang et al.2016. 1y Yang et al.2005. 1y Wong et al.2005. 5y Yu et al.2005. 5y Yu et al.2005. 5y Yu et al.2004. 4y Yerokun et al.2016. 1y, A Youk et al.2015. 5y Piero et al.2015. 5y Piero et al.2015. 5y Piero et al.2005. 5y Yu et al.2004. 5y		RR (95% CI) 283 (2 19, 3 64) 422 (168, 10,59) 238 (2 00, 2 84) 231 (149, 3 26) 133 (1 67, 1 52) 238 (1 67, 1 32) 239 (2 13, 4 20) 239 (2 13, 4 20) 239 (2 13, 4 20) 239 (2 13, 4 20) 249 (2 13, 4 20) 256 (1 30, 3 33) 1.47 (149, 172) 256 (1 30, 3 43) 1.47 (149, 172) 256 (1 27, 2 40) 266 (1 47, 2 65) 265 (1 27, 2 40) 265 (1 27, 2 40) 265 (1 27, 2 50) 265 (1 27, 2 50) 278 (1 86, 3 64) 370 (1 61, 5 64) 300 (1 68, 3 64) 377 (1 61, 129) 278 (1 88, 461) 278 (1 88, 461) 266 (1 88, 361) 377 (1 61, 129) 278 (1 88, 461) 266 (1 68, 3 64) 377 (1 61, 128) 177 (1 61, 217) 288 (2 45, 3 40) 292 (2 24, 3 44) 292 (2 24, 3 44) 292 (2 24, 3 44) 292 (2 12, 247) 200 (1 72, 2 32) 200 (1 72, 2 32) 201 (1 2, 2 32) 201 (1 3, 3 400) 201 (1 2, 2 32) 201 (1 3, 3 400) 201 (1 4 3, 3 400) 201	Events, Screen 286/392 10/30 83/103 48/87 49/87 49/87 49/87 49/87 49/87 49/87 49/87 49/87 49/87 40/87 40/87 40/87 40/87 40/87 40/84 40/56 40/68 40/56 40/68 40/56 40/68	Events, No screen 47/182 6/76 116/343 27/128 3/86 2/4/70 3/65 2/4/72 3/65 2/4/72 3/65 2/4/72 10/162 9/4/221 3/65 2/4/72 2/9/118 10/162 2/9/4/73 10/162 6/7/83 10/162 6/7/83 10/162 10/162 10/162 10/162 10/162 10/162 10/162 10/162 10/17 10/162 10/17 10/162 10/17 10/17 10/17 10/162 10/17 1	Weight (%) 2.27 0.58 2.69 1.69 2.49 1.69 1.69 1.69 1.69 1.69 1.69 1.69 1.69 1.79 2.76 2.38 1.79 2.76 2.39 1.79 2.76 2.31 1.79 1.24 2.76 2.31 1.59 0.68 2.09 1.24 2.76 2.31 1.59 0.68 2.69 1.24 2.76 2.31 1.59 0.68 2.69 1.24 2.63 2.69 1.32 2.63 2.69 1.32 2.63 2.69 1.32 2.63 2.69 1.32 2.63 2.69 1.32 2.63 2.69 1.32 2.63 2.69 1.32 2.63 2.69 1.32 2.63 2.69 1.32 2.63 2.69 1.32 2.63 2.69 1.32 2.63 2.69 1.32 2.65 2.44 2.65 2.44 2.65 2.44 2.65 2.24 2.65 2.44 2.65 2.24 2.65 2.24 2.65 2.24 2.65 2.24 2.65 2.24 2.65 2.24 2.65 2.24 2.65 2.24 2.65 2.24 2.65 2.26 2.24 2.65 2.26 2.24 2.65 2.26 2.44 2.65 2.26 2.26 2.26 2.44 2.65 2.26 2.26 2.22 2.44 2.66 2.22 2.44 2.66 2.22 2.44 2.66 2.22 2.44 2.66 2.22 2.44 2.66 2.21 2.68 2.68 2.48 1.40 0.87 1.00,00 1.92 2.178 3.0777 2.178 3.0777 2.178 3.0777
Ji ef al.2018.4y Subtotal (I-squared = 50.4%, p = 0.109) NOTE: Weights are from random effects analysis		1.58 (0.81, 3.09) 2.68 (1.77, 4.06)	13/57 216/492	15/104 47/322	21.78 100.00
.0556	1 18				

Fig. 6. Comparison of proportion of early hepatocellular carcinoma between the screening group and the non-screening. CI, confidence interval; RCT, random clinical trail; RR, risk ratio; Y, years.

Study ID	Events	Total			Proportion (95%CI)	Weight(%)
3 years of follow-up						
Atiq <i>et al</i> . 2017.3y	187	680			27.50 (23.56, 31.44)	24.48
					27.50 (23.56, 31.44)	24.48
2 years of follow-up						
Singal et al.2021.2y	54	614			8.79 (6.45, 11.14)	25.64
Konerman et al.2019.2y	169	999			16.92 (14.37, 19.47)	25.52
Frey et al.2015.2y	35	285			12.28 (8.21, 16.35)	24.37
Subgroup, DL (I ² =90.5%, p <	< 0.001)				12.66 (7.25, 18.07)	75.52
Heterogeneity between grou	ps: p = 0.000					
Overall, DL (l ² =95.7%, p < 0.	.001)				> 16.30 (8.92, 23.67)	100.00
			-20%	1 I 0 20%		

Fig. 7. Pooled proportion of physiological harm. CI, confidence interval; DL, discrete logarithm; RCT, random clinical trail; USA, the United States of America; Y, years.

a great heterogeneity in pooled proportion of physiological harm. Therefore it is necessary to be cautious in quoting it.

4. Discussion

4.1. Benefits of HCC screening versus non-screening

In this meta-analysis, evidence from RCTs indicated that HCC screening reduced HCC mortality by 47%, prolonged overall survival regardless of length of follow-up, and increased the proportion of early HCC. Similarly, meta-analyses of cohort studies have indicated that HCC screening is more effective than non-screening. The strength of evidence of all outcomes was very low. Subgroup analysis indicated that the benefits of screening may differ according to screening intervals, adjusting for lead time bias, location of study, and mean age.

One meta-analysis, published by Singal et al. in 2014, conducted a systematic review to quantitatively evaluate the benefits of HCC screening.¹⁹ It included 47 observational studies that compared the proportion of early HCC (odds ratio [OR], 2.08 [95% CI, 1.80–2.52]) and 3-year

Study ID	Event	s Total			Proportion % (95%CI)	Weight (%)
Mild						
Atig <i>et al</i> . 2017.3v	118	680		•	- 17.35 (14.22, 20.48)	31.68
Singal et al.2021.2y	44	614			7.33 (5.19, 9.47)	33.85
Konerman <i>et al</i> .2019.2y	84	999			8.41 (6.61, 10.21)	34.47
Group, DL (I ² = 93.2%, p < 0	.001)			>	10.88 (5.80, 15.95)	100.00
Moderate						
Atiq <i>et al</i> . 2017.3y	66	680	•	-	9.71 (7.36, 12.05)	32.49
Singal et al.2021.2y	9	614			1.47 (0.51, 2.42)	34.16
Konerman et al.2019.2y	80	999			8.01 (6.25, 9.76)	33.35
Group, DL (I ² = 97.1%, p <	0.001)				6.32 (0.82, 11.83)	100.00
Severe						
Atiq <i>et al.</i> 2017.3y	3	680	•		0.44 (-0.06, 0.94)	21.09
Singal et al.2021.2y	1	614	•		0.16 (-0.16, 0.48)	51.59
Konerman et al.2019.2y	5	999	•		0.50 (0.06, 0.94)	27.32
Group, DL ($I^2 = 0.0\%$, p = 0	.406)		◊		0.31 (0.08, 0.54)	100.00
		1			1	
		-20%	0	2	0%	

Fig. 8. Pooled proportion of different levels of physiological harm. CI, confidence interval; DL, discrete logarithm.

survival rate ((OR, 1.90 [95% CI, 1.67–2.77]) between HCC screening and no screening groups in cirrhosis patients. In addition, another metaanalysis published by Singal et al. in 2022²¹ was an update of the metaanalysis published in 2014, which evaluated the benefits and harms of HCC screening in patients with cirrhosis from cohort studies. In terms of benefit outcomes, it reported similar results as the meta-analysis in 2014. The results of our meta-analysis are similar to the main results of those two previous meta-analyses. However, the previous studies only evaluated the benefits of HCC screening in patients with cirrhosis. Our meta-analysis included 67 studies, including four RCTs and 63 cohort studies. Our study also evaluated the screening benefits for all high-risk populations (those with HBV, HCV, cirrhosis, and/or another chronic liver disease). In addition, we pooled HCC mortality.

The personal and public health consequences of HCC are enormous, and even a small benefit from screening could save many lives. The general goal of cancer screening is to decrease cancer mortality or increase survival in cancer patients by focusing on detecting cancer patients as early as possible.⁵ Prognosis for HCC patients depends on tumor stage, with curative therapies only available for patients detected at an early stage. Patients detected at an early stage can achieve higher 5-year survival rates with transplant or resection, whereas those with advanced HCC are only eligible for palliative treatments and have a median survival of less than 1 year.^{12,13} Our findings suggest that HCC screening can reduce HCC mortality and prolong overall survival, which increases the proportion of early HCC.

In practice, the 6-month screening interval is recommended by guidelines.^{6,8} Our subgroup analysis supports this recommendation, suggesting that this recommendation should be followed to realize the benefits of screening. Our subgroup analyses also suggest that lead-time bias may exaggerate the benefits of screening. Therefore, tumor volume doubling time (TVDT) can be used to adjust the lead-time bias to the real benefits of HCC screening.⁹⁰ We also found substantial differences according to study location. This may be related to the differences in characteristics of screening population, medical level and cancer screening rate in different countries. Age of patients also affects the benefits of HCC screening. Incidences of HCC and age are directly correlated until approximately 75 years of age in most populations.² The incidence of disease is closely related to the benefits of screening.

4.2. Harms of HCC screening

Three case series studies and one cohort study reported the proportion of physiological harm. The meta-analysis indicated that the pooled proportion of physiological harm was 16.3%, and most harms were of a mild to moderate severity, with few patients experiencing severe harm. The results of subgroup analysis showed different proportions of physiological harm in the 2- and 3-year follow-up subgroups. The results suggest that the proportion of physiological harm increased with an extension of follow-up years. Although an increase in the number of follow-up years can increase the proportion of early HCC, the resulting proportion of physiological harm should not be ignored.

At present, only one meta-analysis, published by Singal et al. in 2022,²¹ has summarized the evidence on HCC screening-related harms. However, it only describes proportions of screening-related physiological harm reported by current articles. In addition, high-quality systematic reviews performed by the USPSTF on breast cancer, cervical cancer, colorectal cancer, lung cancer, and others have shown that cancer screening causes psychological harms such as psychological anxiety. $^{14\!-\!16}$ However, there were no studies have reported or quantified the psychological harms caused by HCC screening. Only three studies have reported the proportion of physiological harm. Screen-relevant physiological harm can include direct complications of screening tests and subsequent diagnostic testing, whether invasive or noninvasive.⁹⁷ Although most common screening modalities (e.g., US and AFP) cause minimal direct physiological harm, they can lead to high rates of diagnostic imaging for false-positive or indeterminate lesions. Imaging modalities such as CT and MRI are associated with contrast injury, radiation exposure, and high cost. Liver biopsy may be required for liver lesions not detected by CT or MRI and can be associated with bleeding, tumor seeding, and/or injury to nearby organs.98,99 A review indicated that screening in patients with liver function child Pugh C who are not transplant candidates may cause over diagnosis.97 The evidence of harms from HCC screening is insufficient.

4.3. Strengths and limitations

A major strength of our study is that we comprehensively evaluated the benefits and harms of HCC screening in all high-risk populations by including both RCTs and observational studies. We also used the GRADE approach to assess the quality of evidence.

Some limitations to our systematic review should be acknowledged. First, most evidence came from retrospective studies in which all patients with diagnosed HCC were first identified and then the screening status was determined. These studies tended to suffer selection bias, lead-time bias, and length bias. Second, the evidence on harms in HCC screening is insufficient, with only four studies available. Finally, other factors including US operator experience and technique, patient body habitus, and liver nodularity may have led to heterogeneity between studies, which we were unable to explore given the lack of data.

In conclusion, the currently available, very low-quality evidence shows that the benefits of HCC screening are better than non-screening. Current evidence of the harms of HCC screening is insufficient. Highquality trials that examine the balance of benefits and harms of HCC screening in populations with chronic liver disease and other high-risk population should be considered in the future.

Declaration of competing interest

The authors declare that they have no conflict of interests.

Data availability

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Acknowledgments

The work was supported by the National Natural Science Foundation of China (grant numbers: 71673003, 72074011).

Author contributions

F.S. and J.Y. conceived the study. Z.Y. and J.Y. drafted the protocol. F.S. and J.Y. conducted the literature search. J.Y., S.Y. selected the studies. J.Y., S.Y., X.Z. and L.G. extracted the data. J.Y. and S.Y. assessed the quality of evidence using the GRADE framework. Z.Y. and F.S. verified the data. J.Y. analyzed the data and wrote the manuscript. Y.J. gave opinions on data analysis. All authors have approved final draft of the manuscript.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jncc.2023.02.001.

Reference

- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68(6):394–424.
- McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. *Hepatology*. 2021;73(Suppl 1):4–13 (Suppl 1). doi:10.1002/hep.31288.
- Zheng RS, Zeng HM, Wang SM, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1–9.
- Metrics GH. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017;390(10100):1260–1344. doi:10.1016/s0140-6736(17)32130-x.
- WHO. Cancer screening 2012. Available from: http://www.who.int/cancer/ prevention/diagnosis-screening/screening/en/.
- Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology*. 2018;67(1):358–380. doi:10.1002/hep.29086.
- Omata M, Cheng AL, Kokudo N, et al. Asia–pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int.* 2017;11(4):317–370. doi:10.1007/s12072-017-9799-9.
- Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019.
- Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417–422.
- Harris RP, Wilt TJ, Qaseem A. A value framework for cancer screening: advice for high-value care from the American college of physicians. *Ann Intern Med.* 2015;162(10):712–717. doi:10.7326/M14-2327.
- 11. WHO. National cancer control programmes:policies and managerial guidelines Second edition. 2002.

- Rognoni C, Ciani O, Sommariva S, et al. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and metaanalyses. Oncotarget. 2016;7(44):72343–72355. doi:10.18632/oncotarget.11644.
- Facciorusso A, Abd El Aziz MA, Sacco R. Efficacy of regorafenib in hepatocellular carcinoma patients: a systematic review and meta-analysis. *Cancers*. 2019;12(1) (Basel). doi:10.3390/cancers12010036.
- Humphrey L., Deffebach M., Pappas M., et al. Screening for lung cancer: systematic review to update the U.S. preventive services task force recommendation 2013. Available from: https://www.uspreventiveservicestaskforce.org/.
- Lin J.S., Piper M.A., Perdue L.A., et al. Screening for colorectal cancer: a systematic review for the U.S. preventive services task force 2016. Available from: https://www.uspreventiveservicestaskforce.org/.
- Nelson H.D., Cantor A., Humphrey L., et al. Screening for breast cancer: a systematic review to update the 2009 U.S. preventive services task force recommendation 2016. Available from: https://www.uspreventiveservicestaskforce.org/.
- Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. *Cochrane Database Syst Rev.* 2012(9):CD002799. doi:10.1002/14651858.CD002799.pub2.
- Kansagara D, Papak J, Pasha AS, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med. 2014;161(4):261–269. doi:10.7326/M14-0558.
- Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. *PLoS Med.* 2014;11(4). doi:10.1371/journal.pmed.1001624.
- Wun YT, Dickinson JA. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. *Cochrane Database Syst Rev.* 2003(2):CD002799 Update in: Cochrane Database Syst Rev. 2012;9:CD002799. doi:10.1002/14651858.CD002799.
- Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77(1):128–139. doi:10.1016/j.jhep.2022.01.023.
- Kramer BS, Croswell JM. Cancer screening: the clash of science and intuition. Annu Rev Med. 2009;60:125–137.
- Atiq O, Tiro J, Yopp AC, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. *Hepatology*. 2017;65(4):1196–1205. doi:10.1002/hep.28895.
- Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
- Wells G.A., Wells G., Shea B., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014.
- NICE. Appendix 4 quality of case series form 2015. Available from: http://www.nice.org.uk/guidance/index
- Díaz-González Á, Forner A. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2016;30(6):1001–1010. doi:10.1016/j.bpg.2016.10.006.
- Guyatt GH, AD Oxman, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924–926. doi:10.1136/bmj.39489.470347.AD.
- 29. Tanaka S, Kitamura T, Nakanishi K, et al. Effectiveness of periodic checkup by ultrasonography for the early diagnosis of hepatocellular carcinoma. *Cancer*. 1990;66(10):2210–2214.
- Martínez Cerezo FJ, Puig M, Martínez Nogueras A, et al. Value of ultrasonography in the early diagnosis of hepatocellular carcinoma. *Rev Esp Enferm Dig.* 1993;84(5):311–314.
- Garcia Gullon C, Rendon Unceta P, Martin Herrera L, et al. Usefulness of ultrasonography in the early diagnosis of hepatocarcinoma in patients with liver cirrhosis. *Rev Esp Enferm Dig.* 1995;87(11):798–801.
- Wong LL, Limm WM, Severino R, et al. Improved survival with screening for hepatocellular carcinoma. *Liver Transpl.* 2000;6(3):320–325. doi:10.1053/lv.2000.4875.
- Lu J, Shu YX, Lin WY, et al. Study of AFP andbimaging monitor diagnosis of small hepatocellular carcinoma in high-risk hepatocellular subjects. J Appl Radiol. 2001(6):405–407.
- 34. Chen TH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer. 2002;98(2):257–261.
- Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10(4):204–209. doi:10.1258/096914103771773320.
- Youk CM, Choi MS, Paik SW, et al. Early diagnosis and improved survival with screening for hepatocellular carcinoma. *Taehan Kan Hakhoe Chi*. 2003;9(2):116–123.
- Trevisani F, Cantarini MC, Labate AM, et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. *Am J Gastroenterol.* 2004;99(8):1470–1476. doi:10.1111/j.1572-0241.2004.30137.x.
- Kemp W, Pianko S, Nguyen S, et al. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol. 2005;20(6):873–881. doi:10.1111/j.1400-1746.2005.03844.x.
- Taura N, Hamasaki K, Nakao K, et al. Clinical benefits of hepatocellular carcinoma surveillance: a single-center, hospital-based study. Oncol Rep. 2005;14(4):999–1003.
- 40. Van Vlierberghe H, Colle I, Henrion J, et al. The HepCar registry: report on a one-year registration program of hepatocellular carcinoma (HCC) in Belgium. What is daily practice in HCC? Acta Gastroenterol Belg. 2005;68(4):403– 411.
- 41. Ando E, Kuromatsu R, Tanaka M, et al. Surveillance program for early detection of

hepatocellular carcinoma in Japan: results of specialized department of liver disease. J Clin Gastroenterol. 2006;40(10):942–948.

- Cheung TK, Lai CL, Wong BC, et al. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther. 2006;24(4):573–583. doi:10.1111/j.1365-2036.2006.03029.x.
- Tanaka H, Nouso K, Kobashi H, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. *Liver Int.* 2006;26(5):543–551. doi:10.1111/j.1478-3231.2006.01270.x.
- 44. Toyoda H, Kumada T, Kiriyama S, et al. Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. *Clin Gastroenterol Hepatol.* 2006;4(9):1170–1176.
- Caumes JL, Nousbaum JB, Bessaguet C, et al. Epidemiology of hepatocellular carcinoma in Finistere. Prospective study from June 2002 to May 2003. *Gastroenterol Clin Biol.* 2007;31(3):259–264.
- Davila JA, Weston A, Smalley W, et al. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2007;41(8):777–782.
- Gellert L, Jalaludin B, Levy M. Hepatocellular carcinoma in Sydney South West: late symptomatic presentation and poor outcome for most. *Intern Med J.* 2007;37(8):516–522.
- 48. Leykum LK, El-Serag HB, Cornell J, et al. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. *Clin Gastroenterol Hepatol.* 2007;5(4):508–512.
- Trevisani F, Santi V, Gramenzi A, et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? *Am J Gastroenterol.* 2007;102(11):2448–2457 quiz 58. doi:10.1111/j.572-0241.2007.01395.x.
- Pascual S, Irurzun J, Zapater P, et al. Usefulness of surveillance programmes for early diagnosis of hepatocellular carcinoma in clinical practice. *Liver Int.* 2008;28(5):682– 689. doi:10.1111/j.1478-3231.2008.01710.x.
- Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. *Hepatology*. 2008;48(4):1149–1156.
- Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. *Am J Med.* 2008;121(2):119–126.
- Wong GLH, Wong VWS, Tan GM, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. *Liver Int.* 2008;28(1):79–87. doi:10.1111/j.1478-3231.2007.01576.x.
- El-Zayadi AR, Badran HM, Shawky S, et al. Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients. *Hepatol Int.* 2010;4(2):500–506. doi:10.1007/s12072-010-9170-x.
- Jou JH, Chen PH, Jazwinski A, et al. Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center. *Dig Dis Sci.* 2010;55(12):3591–3596. doi:10.1007/s10620-010-1366-3.
- Kuo YH, Lu SN, Chen CL, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. *Eur J Cancer*. 2010;46(4):744–751. doi:10.1016/j.ejca.2009.12.018.
- Noda I, Kitamoto M, Nakahara H, et al. Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2010;45(1):105–112. doi:10.1007/s00535-009-0131-x.
- Tong MJ, Sun HE, Hsien C, et al. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. *Dig Dis Sci.* 2010;55(3):826–835. doi:10.1007/s10620-009-1059-y.
- 59. Zapata E, Zubiaurre L, Castiella A, et al. Are hepatocellular carcinoma surveillance programs effective at improving the therapeutic options? *Rev Esp Enferm Dig.* 2010;102(8):484–488.
- El-Serag HB, Kramer JR, Chen GJ, et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. *Gut.* 2011;60(7):992–997. doi:10.1136/gut.2010.230508.
- 61. Rodríguez RG, Gutiérrez MR, de Frutos CG, et al. Características clínicas, estadificación y tratamiento de los pacientes con carcinoma hepatocelular en la práctica clínica. Estudio prospectivo de una serie de 136 pacientes [Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients]. Gastroenterol Hepatol. 2011;34(8):524–531 OctSpanish. doi:10.1016/j.gastrohep.2011.06.009.
- 62. Stroffolini T, Trevisani F, Pinzello G, et al. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. *Dig Liver Dis.* 2011;43(11):875–880.
- Yang JD, Harmsen WS, Slettedahl SW, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. *Clin Gastroenterol Hepatol.* 2011;9(7):617–623 e1Epub Apr 1. doi:10.1016/j.cgh.2011.03.027.
- 64. Miquel M, Sopeña J, Vergara M, et al. Factors related to survival in hepatocellular carcinoma in the geographic area of Sabadell (Catalonia, Spain). *Rev Esp Enferm Dig.* 2012;104(5):242–247.
- Sarkar M, Stewart S, Yu A, et al. Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. J Viral Hepat. 2012;19(8):594–600. doi:10.1111/j.1365-2893.2011.01577.x.
- 66. Gaba RC, Kallwitz ER, Parvinian A, et al. Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients. *Ann Hepatol.* 2013;12(5):766–773.
- Eltabbakh M, Zaghla H, Abdel-Razek W, et al. Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. *Med Oncol.* 2015;32(1):432. doi:10.1007/s12032-014-0432-7.
- 68. Yeh YP, Hu TH, Cho PY, et al. Evaluation of abdominal ultrasonography mass screen-

ing for hepatocellular carcinoma in Taiwan. Hepatology. 2014;59(5):1840-1849. doi:10.1002/hep.26703.

- 69. Farrell C, Cross TJ, Halpen A, et al. The evaluation of an automated recall programme for surveillance liver ultrasound in patients at increased risk of hepatocellular carcinoma. J Hepatol. 2015;62:S443–S4S4.
- Frey RS, Boldanova T, Heim M. Ultrasound surveillance for hepatocellular carcinoma: real-life performance in a hepatology outpatient clinic. Swiss Med Wkly. 2015;145:w14200. doi:10.4414/smw.2015.14200.
- Nusbaum JD, Smirniotopoulos J, Wright HC, et al. The effect of hepatocellular carcinoma surveillance in an urban population with liver cirrhosis. World J Gastroenterol. 2015;21(10):3035–3040. doi: 10.748/wjg.v21.i10
- Nusbaum JD, Smirniotopoulos J, Wright HC, et al. The effect of hepatocellular carcinoma surveillance in an urban population with liver cirrhosis. J Clin Gastroenterol. 2015;49(10):e91–ee5.
- Poh Z, Goh BB, Chang PE, et al. Surveillance for hepatocellular carcinoma in a mixedaetiology UK cohort with cirrhosis: does alpha-fetoprotein still have a role? *Eur J Gastroenterol Hepatol.* 2015;27(6):638–643. doi:10.1097/MEG.00000000000341.
- 74. Thein HH, Campitelli MA, Yeung LT, et al. Improved survival in patients with viral hepatitis-induced hepatocellular carcinoma undergoing recommended abdominal ultrasound surveillance in ontario: a population-based retrospective cohort study. *PLoS One*. 2015;10(9):e0138907. doi:10.1371/journal.pone. eCollection 2015.
- Van Meer S, De Man RA, Coenraad MJ, et al. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands. J. Hepatol. 2015;63(5):1156–1163. doi:10.1016/j.jhep.2015.06.012.
- Chin J, Cheng W, Kong J, et al. The effect of omitting alfa-fetoprotein in surveillance of hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:97. doi:10.1111/jgh.13520.
- 77. Costentin C, Layese R, Bourcier V, et al. Prospective evidence that hepatocellular carcinoma surveillance in patients with compensated viral cirrhosis increases the probability of curative treatment and survival taking into account lead-time bias (ANRS CO12 CIRVIR cohort). J Hepatol. 2016;64(2):S194–S195.
- Demma S, O'Donoghue P, O'Beirne J, et al. False-negative liver ultrasound limits benefits of HCC surveillance. J Hepatol. 2016;64(2):S340–S341.
- **79.** Khalaf N, Ying J, Mittal S, et al. Natural history of untreated HCC in a US cohort and the role of cancer surveillance. *Gastroenterology*. 2016;150(4):S1130.
- Mittal R, Sahota A, Tung J, et al. Impact of screening on survival in hepatocellular carcinoma patients with chronic hepatitis B-A regional U.S. population based study. *Hepatology*. 2016;64(1):669A.
- Mittal S, Kanwal F, Ying J, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort. *J Hepatol.* 2016;65(6):1148–1154. doi:10.1016/j.jhep.2016.07.025.
- Yerokun OA, Parikh ND, Scaglione SJ, et al. HCC surveillance is associated with early tumor detection and improved survival: a multi-center United States study. *Gastroen*terology. 2016;150(4):S1138.
- Chen JG, Zhang YH, Zhu J, et al. Early diagnosis and early treatment for liver cancer in Qidong: survival of patients and effectiveness of screening. *Chin J Oncol.* 2017(12):946–951.
- Chaiteerakij R, Chattieng P, Choi J, et al. Surveillance for hepatocellular carcinoma reduces mortality: an inverse probability of treatment weighted analysis. *Ann Hepatol.* 2017;16(3):421–429. doi:10.5604/16652681.1235485.
- Rich NE, Yopp AC, Marrero JA, et al. Hepatocellular carcinoma surveillance using ultrasound and afp improves early detection and survival in patients with cirrhosis. *Hepatology*. 2017;66:730A.
- Tong MJ, Rosinski AA, Huynh CT, et al. Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. *Hepatol Commun.* 2017;1(7):595–608.
- Dixon S, Longhurst A, Murgatroyd J, et al. Hepatocellular carcinoma (HCC) surveillance in clinical practice: a district general hospital single-centre experience. *Gut.* 2018;67:A123. doi:10.1136/gutjnl-2018-BSGAbstracts.245.
- Ji M, Liu Z, Chang ET, et al. Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China. *Sci Rep.* 2018;8(1):12787. doi:10.1038/s41598-018-31119-9.
- Kim HY, Nam JY, Lee JH, et al. Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. *Aliment Pharmacol Ther.* 2018;47(11):1490–1501. doi:10.1111/apt.14623.
- Toyoda H, Kumada T, Tada T, et al. Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: a novel approach for the adjustment of lead-time bias. *Liver Int.* 2018;38(12):2260–2268.
- Bui C.N. Impact of surveillance and early-stage versus late-stage hepatocellular carcinoma (HCC) detection on patient overall survival 2019.
- Chinnaratha MA, Campbell K, Mathias R, et al. Improved survival of hepatocellular carcinoma patients diagnosed with a dedicated screening programmea propensity score adjusted analysis. J Gastrointest Cancer. 2019;50(4):888–893. doi:10.1007/s12029-018-0171-7.
- Im S, Jang ES, Lee JH, et al. Surveillance rate and its impact on survival of hepatocellular carcinoma patients in South Korea: a cohort study. *Cancer Res Treat*. 2019;51(4):1357–1369. doi:10.4143/crt.2018.430.
- Konerman MA, Verma A, Zhao B, et al. Frequency and outcomes of abnormal imaging in patients with cirrhosis enrolled in a hepatocellular carcinoma surveillance program. *Liver Transpl.* 2019;25(3):369–379.
- 95. Piñero F, Rubinstein F, Marciano S, et al. Surveillance for hepatocellular carcinoma:

does the place where ultrasound is performed impact its effectiveness? Dig Dis Sci.

- does the place where ultrasound is performed impact its effectiveness? *Dig Dis Sci.* 2019;64(3):718–728. doi:10.1007/s10620-018-5390-z.
 96. Singal AG, Patibandla S, Obi J, et al. Benefits and harms of hepatocellular carcinoma surveillance in a prospective cohort of patients with cirrhosis. *Clin Gastroenterol Hepatol.* 2021;19(9):1925–1932 Sepe1. doi:10.1016/j.cgh.2020.09.014.
 97. Rich NE, Parikh ND, Singal AG. Overdiagnosis: an understudied issue in hepatocellular carcinoma surveillance. *Semin Liver Dis.* 2017;37(4):296–304. doi:10.1016/j.cgh.2027.1600721600721
- doi:10.1055/s-0037-1608775.
- 98. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20mm or smaller in Forner A, Vilana R, Ayuso C, et al. Diagnosis of nepatic nodules 20mm of smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocel-lular carcinoma. *Hepatology*. 2008;47(1):97–104. doi:10.1002/hep.21966.
 Rockey DC, Caldwell SH, Goodman ZD, et al. American association for the study of liver diseases. Liver biopsy. *Hepatology*. 2009;49(3):1017–1044. doi:10.1002/hep.20740
- doi:10.1002/hep.22742.